Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Tahara M, Oeda T, Sawada H. Seeking transpaRINcy for rituximab dosing in NMOSD - Authors' reply. Lancet Neurol 2020;19:716-717. [PMID: 32822625 DOI: 10.1016/s1474-4422(20)30281-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2020] [Accepted: 07/16/2020] [Indexed: 11/26/2022]

For:	Tahara M, Oeda T, Sawada H. Seeking transpaRINcy for rituximab dosing in NMOSD - Authors' reply. Lancet Neurol 2020;19:716-717. [PMID: 32822625 DOI: 10.1016/s1474-4422(20)30281-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2020] [Accepted: 07/16/2020] [Indexed: 11/26/2022]

Number	Cited by Other Article(s)
1	Tahara M, Tomoko O, Okada K, Ochi K, Maruyama H, Fukaura H, Nomura K, Shimizu Y, Nakashima I, Misu T, Umemura A, Yamamoto K, Sawada H. Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration. Mult Scler Relat Disord 2022;60:103730. [DOI: 10.1016/j.msard.2022.103730] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2021] [Revised: 03/02/2022] [Accepted: 03/05/2022] [Indexed: 11/24/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse Affiliation(s) Collapse

Number

Cited by Other Article(s)

Tahara M, Tomoko O, Okada K, Ochi K, Maruyama H, Fukaura H, Nomura K, Shimizu Y, Nakashima I, Misu T, Umemura A, Yamamoto K, Sawada H. Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration. Mult Scler Relat Disord 2022;60:103730. [DOI: 10.1016/j.msard.2022.103730] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2021] [Revised: 03/02/2022] [Accepted: 03/05/2022] [Indexed: 11/24/2022]